Pharmasset impresses with oral HepC treatment

Investors appear bullish about Pharmasset ($VRUS) after the developer showed off some intriguing data on a therapy against Hepatitis C that doesn't require injections like regiments that include Merck's ($MRK) and Vertex's ($VRTX) drugs do. The Street's Adam Feuerstein reported this morning that the liver-damaging virus was at undetectable levels in 10 patients who got a combo of Pharmasset's experimental PSI-7977 and ribavirin--both oral drugs--after four weeks of treatment.

Pharmasset's PSI-7977 has been a closely watched drug candidate in the white-hot HepC market. Today, the company's stock price jumped on the data included in an abstract for November's American Association of the Study of Liver Disease annual meeting, Feuerstein reports. The data provide promise that the experimental drug could rapidly wipe out the virus without patients having to take injections of interferon, reducing some of the complexity and potential side effects of treatment.

Shares of Pharmasset were trading at about $83.50 this morning, up about 8% and nearing the high end of its 52-week range of $76.25 and $85.32, according to Google Finance.

- read Feuerstein's report

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.